clinical efficacy of Shengxuening tablets for cancer anemia:a randomized, double-blind study

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients are diagnosed as gastrointestinal tumours by imaging, pathological and/or cytological;
•2. Patients meet the diagnostic criteria for mild or moderate anemia (mild anemia: Hb 90 to 120g/L or moderate anemia: Hb 60 to 90g/L), peripheral blood film shows small cell hypochromic anemia (MCV<80fl, MCH<27pg, MCHC<0.32, or red blood cell morphology may have obvious hypochromic manifestations); serum (plasma) iron <8.95µmol/L (50µg/L); total iron binding capacity>64.44µmol/L (360µg/dl); serum ferritin (SF) <14µg/L or transferrin saturation <0.15.
•3. Aged 18 to 75 years;
•4. KPS score above 70;
•5. Life expecting longer than three months;
•6. Any medication not be used to treat anemia and improving fatigue within one month before enrollment;
•7. No chemotherapy regimen had been used before enrollment or had been discontinued for at least one month;
•8. Voluntary subjects and signed informed consent.

•1. With heart, liver, kidney and other important organ damage.
•2. Pregnant women and mental patients.
•3. With gastric cancer invading the blood vessels caused by hematemesis, blood in the stool and other major bleeding.
•4. Patients did not use the drug as prescribed.
•5. Patient was forced to interrupt treatment due to serious side effects during the treatment period.

发起方

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine